Skip to main
NBIX
NBIX logo

Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

Neurocrine Biosciences (NBIX) Analyst Ratings

Based on 34 analyst ratings
Buy
Strong Buy 41%
Buy 38%
Hold 21%
Sell 0%
Strong Sell 0%

Bulls say

Neurocrine Biosciences Inc is poised for growth due to an increasing patient population for congenital adrenal hyperplasia (CAH), which has expanded by 3,000 patients since 2018, indicating a rising demand for targeted treatments. The company's product Crenessity has the potential to significantly reduce the clinical consequences of androgen excess, suggesting a valuable addition to its treatment offerings in managing related complications. Additionally, a focus on educating prescribers and improving access will likely enhance market penetration and sustain the momentum of product launches, further supporting a positive long-term outlook for the company's stock.

Bears say

Neurocrine Biosciences faces a negative outlook primarily due to a downward revision in its revenue assumptions for the drug Ingrezza, which now reflects challenges such as slower growth, competitive pressures, and complexities in payer dynamics, reducing the anticipated revenue from $2,846 million to $2,648 million by the end of 2025. Additionally, the company is exposed to significant risks that could impact its investment thesis, including potential failures in clinical studies, the inability to secure regulatory approvals, and the threat of a smaller-than-expected commercial opportunity stemming from market size and competition. These factors collectively contribute to concerns regarding the overall financial performance and growth prospects of Neurocrine Biosciences.

Neurocrine Biosciences (NBIX) has been analyzed by 34 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 38% recommend Buy, 21% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neurocrine Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neurocrine Biosciences (NBIX) Forecast

Analysts have given Neurocrine Biosciences (NBIX) a Buy based on their latest research and market trends.

According to 34 analysts, Neurocrine Biosciences (NBIX) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $139.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $139.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neurocrine Biosciences (NBIX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.